

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**THEIS et al.**

Examiner: **K.T. Hirianna**

Art Unit: **1633**

Application No.: **10/594419**

Filed: **May 22, 2007**

Title: **Dual-transfected Cells Lines As In Vitro  
Screening Tools For Pharmaceutical Compound  
Profiling: A Model For Heptobiliary Elimination**

**REPLY TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement dated September 30, 2009, Group 1 is elected. Group 1 contains claims 1-2, 4-9, 27-28, and 30-35 drawn to a mammalian cell. As noted by the Examiner, claim 27 has a typographical error and thus claim 27 and those claims dependent therefrom would comprise Group 5. Thus, Group 1 contains claims 102 and 4-9.

Respectfully submitted,  
/Ann Marie Szczepanik/  
Ann Marie Szczepanik, Reg. No. 52,267

sanofi-aventis U.S. LLC  
U.S. Patent Operations  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-4757  
Telefax (908) 231-2626

sanofi-aventis Docket No. DEAV2004/0025 US PCT